ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
[
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to assess the value of C-X-C motif chemokine receptor 4 (CXCR4) targeted positron emission tomography/computed tomography ([18F]AlF-NOTA-QHY-04 PET/CT) imaging in spleen for prediction of degree of myelosuppression in patients with small cell lung cancer (SCLC) before therapy.
methods59 patients with SCLC underwent [18F]AlF-NOTA-QHY-04 PET/CT scanning before treatment. The maximum, mean, and peak standard uptake value (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV) and total lesion CXCR4 expression (TLC) of spleen at baseline were acquired. Chemotherapy-based treatment was administered for limited-stage and extensive-stage SCLC. The most severe degree of myelosuppression during the treatment was recorded. Patients were identified as mild and severe myelosuppression. Potential predictors were identified and validated through intergroup difference analysiis, ROC curve assessment, and ordinal regression analysis.
resultsPatients with severe myelosuppression exhibited significantly higher splenic uptake values (SUVmax, SUVmean, SUVpeak and TLC) compared to those with mild myelosuppression (all p < 0.05). Regions of interest (ROI) curve analysis identified that higher metabolic parameters, including SUVmax (AUC = 0.853, p < 0.0001), SUVmean (AUC = 0.885, p < 0.0001), SUVpeak (AUC = 0.821, p < 0.0001), TLC (AUC = 0.753, p = 0.0016), were significantly associated with more severe myelosuppression. Multivariate analysis identified SUVmax (p = 0.007) and age (p = 0.005) as significant independent predictors of treatment-related myelosuppression severity.
conclusionsOur findings suggest that baseline splenic [18F]AlF-NOTA-QHY-04 PET/CT parameters, particularly SUVmax, may help identify patients with small cell lung cancer who are at high risk of severe treatment-related myelosuppression, with older age serving as an additional clinical risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.